Refine
Has Fulltext
- yes (123)
Is part of the Bibliography
- yes (123)
Year of publication
Document Type
- Journal article (123) (remove)
Keywords
- metabolism (8)
- apoptosis (7)
- SARS-CoV-2 (5)
- cytokinins (5)
- COVID-19 (4)
- leukemic cells (4)
- regulation (4)
- transcriptome (4)
- Candida albicans (3)
- bioinformatics (3)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (119)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (8)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (6)
- Institut für Molekulare Infektionsbiologie (5)
- Center for Computational and Theoretical Biology (4)
- Institut für Experimentelle Biomedizin (4)
- Institut für Pharmakologie und Toxikologie (4)
- Institut für Virologie und Immunbiologie (4)
- Kinderklinik und Poliklinik (3)
- Institut für Humangenetik (2)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 031A408B (1)
- CoG 721016–HERPES (1)
- ESF-ZDEX 4.0 (1)
MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic.